Gilead said Monday its drug, Trodelvy, failed to pass muster in a study of patients with lung cancer, and GILD stock toppled.

The post Gilead Crashes 10%, Sacrificing Its Breakout, On A Surprise Miss In Cancer Treatment appeared first on Investor’s Business Daily.